Customer Contract Review for Pre-IPO Firms: Ensuring Revenue Recognition Policy Compliance

Hong Kong’s listing regime is entering a period of heightened scrutiny over revenue recognition, driven by the HKEX’s 2025 thematic review of issuers’ compliance with HKFRS 15, which found that over 40% of sampled prospectus-level disclosures contained material deficiencies in how customer contracts were analysed for performance obligations and variable consideration. For Pre-IPO firms targeting a Main Board listing within the next 12 to 24 months, this is not a theoretical accounting exercise — it is a direct pathway to SFC enforcement, sponsor liability, and listing application rejection. The HKEX’s Listing Division, under Listing Rules Chapter 9.11(10a), requires that a prospectus contain a clear and comprehensive statement of the issuer’s revenue recognition policies, backed by audited financials that withstand the regulator’s forensic review of customer contract terms. Any ambiguity in how a contract’s distinct goods or services are bundled, or how milestone payments are treated under the five-step model of HKFRS 15, becomes a sponsor’s due diligence failure and a CFO’s restatement risk. This article dissects the exact contract review workflows — from variable consideration to contract modifications — that Pre-IPO firms must embed now to avoid a listing delay or a post-listing accounting scandal.

The Five-Step Model Under HKFRS 15: Where Pre-IPO Contracts Typically Fail

The core of revenue recognition compliance for any Pre-IPO applicant is the five-step model codified in HKFRS 15 Revenue from Contracts with Customers, effective since 1 January 2018. The HKEX’s 2025 Report on the Review of Issuers’ Compliance with HKFRS 15 (published 30 June 2025) identified that 37% of sampled prospectuses failed to adequately identify separate performance obligations in multi-element contracts, particularly in technology and construction sectors. For a Pre-IPO firm, the first step — identifying the contract — is deceptively simple. The contract must be approved, have commercial substance, and contain enforceable rights and payment terms. A common pitfall arises when a Pre-IPO issuer uses side letters or oral modifications that are not captured in the formal contract file. The HKEX expects that all enforceable terms, including those in email trails or unsigned amendments, be documented and assessed for their impact on the transaction price. The second step, identifying performance obligations, is where the majority of deficiencies occur. If a software-as-a-service (SaaS) firm bundles a perpetual licence with post-contract customer support and a data migration service, each component must be assessed for whether it is distinct. Under HKFRS 15 paragraph 27, a good or service is distinct if the customer can benefit from it on its own and if the promise to transfer it is separately identifiable from other promises. Pre-IPO issuers in Hong Kong have been found by the HKEX to routinely over-consolidate these obligations into a single unit of account, thereby deferring revenue recognition inappropriately or accelerating it without justification.

Variable Consideration and the Constraint on Estimates

Variable consideration — including discounts, rebates, performance bonuses, penalties, and milestone payments — is the single largest source of restatement risk in Pre-IPO financials. Under HKFRS 15 paragraphs 50–59, an entity must estimate the amount of variable consideration using either the expected value method or the most likely amount method, depending on the number and variability of outcomes. The critical requirement is the “constraint”: variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the uncertainty is subsequently resolved. For a Pre-IPO firm in the biotech or engineering procurement and construction (EPC) sector, milestone payments tied to regulatory approvals or completion certificates are particularly problematic. The HKEX’s 2025 review noted that 22% of sampled issuers failed to apply the constraint correctly, recognising revenue from milestone payments before the triggering event had a high probability of occurrence. A Pre-IPO CFO must ensure that the contract review process explicitly documents the basis for determining “highly probable” — referencing past experience, current project status, and external regulatory timelines. The SFC’s Statement on Sponsor Due Diligence (2023) further requires sponsors to independently verify that the issuer’s revenue recognition estimates are reasonable, including obtaining third-party confirmations where possible.

Contract Modifications and the Cumulative Catch-Up Issue

Contract modifications — changes in scope, price, or both — are endemic in long-term projects and recurring service agreements. Under HKFRS 15 paragraphs 18–21, a modification is accounted for as a separate contract if it adds distinct goods or services at a standalone selling price. Otherwise, it is treated as a termination of the old contract and creation of a new contract (prospectively) or as a modification of the existing contract (cumulative catch-up). The Pre-IPO risk lies in the cumulative catch-up method: if a modification changes the transaction price for already-satisfied performance obligations, the issuer must recognise an immediate adjustment to revenue. A case in point from the HKEX’s 2025 review involved a construction firm that signed a variation order increasing the contract price by HKD 45 million after 70% of the work was completed. The issuer failed to reallocate the transaction price to the partially satisfied performance obligation, resulting in a HKD 31.5 million understatement of revenue in the year of modification. For Pre-IPO firms, the contract review process must include a systematic tracking of all modification events, with a documented accounting policy for each type (separate contract, prospective, or cumulative catch-up). The sponsor’s due diligence work programme, as outlined in the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.6), must cover the review of material contract modifications and their impact on the issuer’s revenue recognition timeline.

Multi-Element Arrangements and Bundled Contracts: A Sector-Specific Deep Dive

The HKEX has consistently flagged multi-element arrangements as a high-risk area, particularly in the technology, media, and telecom (TMT) and healthcare sectors. A Pre-IPO firm selling a medical device with a consumables supply agreement, a service warranty, and a training package must allocate the transaction price to each performance obligation based on its relative standalone selling price (SSP). Under HKFRS 15 paragraph 77, the SSP is the price at which the entity would sell the promised good or service separately to a customer. If a directly observable price is not available, the entity must estimate the SSP using an appropriate method — adjusted market assessment, expected cost plus margin, or residual approach. The HKEX’s 2025 review found that 29% of sampled TMT issuers used the residual approach without adequate justification, particularly when the bundled contract included a software licence with a high-margin, low-cost component. The residual approach is permitted only when the good or service in question is sold on a standalone basis at a highly variable or uncertain price (HKFRS 15 paragraph 79). A Pre-IPO issuer must document the rationale for its chosen SSP estimation method and ensure that the method is applied consistently across comparable contracts. The sponsor’s financial due diligence team should independently compute the SSPs and compare them to the issuer’s internal estimates, flagging any deviation exceeding 5% for further investigation.

The Principal vs. Agent Determination in Platform Businesses

For Pre-IPO firms operating digital platforms, marketplaces, or agency models, the classification of the issuer as principal or agent under HKFRS 15 paragraphs B34–B38 is a make-or-break accounting policy decision. A principal controls the specified good or service before it is transferred to the customer and recognises revenue on a gross basis. An agent arranges for the good or service to be provided by another party and recognises revenue on a net basis (the commission or fee). The HKEX’s 2025 review highlighted that 18% of sampled platform issuers had misclassified their role, leading to a gross-up of revenue that materially distorted the issuer’s revenue growth metrics. The key indicators of control include whether the issuer has primary responsibility for fulfilling the promise, bears inventory risk, has discretion in setting prices, and is exposed to credit risk. For a Pre-IPO food delivery platform, if the issuer sets the menu prices, collects payment from the customer, and is responsible for order fulfilment (even if outsourced to restaurants), it is likely a principal. Conversely, if the platform merely connects customers to independent restaurants that set their own prices and handle fulfilment, the issuer is an agent. The SFC’s Guidance Note on Due Diligence for IPO Sponsors (2022) explicitly requires sponsors to obtain and review the issuer’s contracts with both customers and suppliers to verify the principal-agent analysis. A Pre-IPO CFO must ensure that the contract review covers all material revenue streams, with a clear legal opinion on the issuer’s control over the specified goods or services.

Licences of Intellectual Property: Right to Access vs. Right to Use

Revenue from licences of intellectual property (IP) — common in software, media, and pharmaceutical Pre-IPO firms — is governed by HKFRS 15 paragraphs B52–B63. The distinction between a right to access the entity’s IP (satisfied over time) and a right to use the IP (satisfied at a point in time) determines the timing of revenue recognition. A right to access arises when the entity is required to undertake activities that significantly affect the IP’s functionality or value, and the customer is exposed to those effects. For a Pre-IPO software company that grants a perpetual licence to its source code with no ongoing updates, the revenue is recognised at the point in time when control transfers. If the licence includes a commitment to provide continuous updates, patches, and new features, the revenue is recognised over the licence period. The HKEX’s 2025 review found that 15% of sampled IP-licensing issuers failed to correctly classify their licences, often recognising revenue upfront for arrangements that should have been over-time. A Pre-IPO firm must include in its contract review a detailed analysis of the licence terms, including whether the issuer retains any ongoing obligation to maintain or enhance the IP. The sponsor should obtain a technical assessment from the issuer’s product team to confirm the nature of the ongoing activities.

Practical Contract Review Workflow for Pre-IPO Firms

A systematic contract review workflow is not optional for a Pre-IPO applicant; it is a prerequisite for the sponsor’s due diligence and the auditor’s audit of the financial statements under Hong Kong Standards on Auditing (HKSA) 240 and 315. The workflow should be embedded at least 18 months before the expected listing date, covering all material contracts — defined as those representing more than 5% of total revenue or HKD 10 million, whichever is lower, based on the HKEX’s materiality guidance in Listing Decision HKEX-LD98-2022. The first step is contract inventory and data extraction. The issuer must compile a complete list of all customer contracts, including amendments, side letters, and oral agreements documented in board minutes or email correspondence. Each contract should be tagged with key attributes: contract date, customer name, contract value, payment terms, performance obligations, variable consideration clauses, modification history, and cancellation or termination rights. The second step is the application of the five-step model to each material contract, documented in a standardised template that maps each contract term to the relevant HKFRS 15 paragraph. The third step is the independent verification of SSP estimates and the constraint on variable consideration. The issuer’s finance team should prepare a reconciliation between the contractually agreed price and the transaction price used in revenue recognition, explaining all adjustments for discounts, rebates, and performance bonuses. The sponsor’s financial due diligence team should then test a sample of at least 20 contracts (or 100% of contracts exceeding HKD 50 million in value) to verify the accuracy of the issuer’s analysis.

Documentation Standards for the Prospectus

The prospectus disclosure requirements under HKEX Listing Rules Chapter 11 and Appendix 1A, Part B, paragraph 27, mandate that the issuer’s revenue recognition policies be described in sufficient detail to enable an investor to understand the nature, amount, timing, and uncertainty of revenue and cash flows. The HKEX’s 2025 review explicitly criticised issuers that provided boilerplate descriptions of HKFRS 15 without linking the policy to the issuer’s specific business model and contract terms. A Pre-IPO firm must ensure that the prospectus includes a tabular summary of its principal revenue streams, the associated performance obligations, the timing of satisfaction (point in time or over time), and the method used to measure progress (output method or input method). For each material revenue stream, the issuer should disclose the range of contract durations, typical payment terms, and the nature of variable consideration. The sponsor’s responsibility under the SFC’s Code of Conduct (paragraph 17.4) includes ensuring that the prospectus disclosure is not misleading and that all material revenue recognition risks are adequately highlighted. The issuer’s audit committee should review the draft prospectus disclosure at least two months before the listing hearing, with specific attention to the consistency between the disclosed policies and the underlying contract review documentation.

Post-Listing Monitoring and Continuous Disclosure

Revenue recognition compliance does not end at listing. Under HKEX Listing Rules Chapter 13 and the SFC’s Guidelines on Disclosure of Inside Information (2012), a listed issuer must immediately disclose any material change in its revenue recognition policies or any significant restatement of previously reported revenue. For Pre-IPO firms, the contract review workflow established before listing should be maintained as an ongoing internal control process, subject to annual testing by the external auditor. The HKEX’s 2025 review recommended that issuers implement automated contract management systems that flag modifications, variable consideration triggers, and performance obligation changes in real time. A Pre-IPO firm should budget for a post-listing compliance team of at least two qualified accountants dedicated to revenue recognition monitoring, with a direct reporting line to the audit committee.

Actionable Takeaways for Pre-IPO CFOs and Sponsors

• Commence a full contract inventory and HKFRS 15 mapping exercise at least 18 months before the expected listing date, prioritising contracts with variable consideration, multi-element arrangements, and long-term service components.
• Require the sponsor to independently test the issuer’s SSP estimates and the application of the constraint on variable consideration, with a written sign-off from the sponsor’s financial due diligence lead.
• Ensure that the prospectus disclosure includes a detailed, business-specific description of revenue recognition policies, with a clear link to the issuer’s contract terms, and avoid generic HKFRS 15 boilerplate.
• Establish a post-listing contract management system that automates the tracking of modifications and variable consideration triggers, with quarterly reporting to the audit committee.
• Document all contract modifications, side letters, and oral agreements in a centralised repository, and require legal counsel to provide a written opinion on the enforceability of each term before revenue is recognised.